Pulmonx Corporation (LUNG) Posts Fourth Quarter Loss, Surpasses Revenue Projections

Pulmonx Corporation Posts Smaller-Than-Expected Quarterly Loss

Pulmonx Corporation (LUNG) reported a quarterly loss of $0.25 per share, which was narrower than the anticipated loss of $0.39 per share according to Zacks Consensus Estimates. In the same quarter last year, the company recorded a loss of $0.33 per share. These results exclude one-time items.

This performance resulted in a positive earnings surprise of 35.9%. In the previous quarter, Pulmonx was projected to lose $0.40 per share but actually reported a loss of $0.34, exceeding expectations by 15%.

For the past four quarters, Pulmonx has consistently outperformed consensus earnings per share estimates.

Operating within the Zacks Medical Info Systems sector, Pulmonx generated $22.6 million in revenue for the quarter ending December 2025, beating the consensus estimate by 3.97%. This figure is slightly lower than the $23.76 million reported in the same period last year. The company has surpassed revenue expectations in each of the last four quarters.

The direction of Pulmonx’s stock price in the near term will largely depend on management’s insights during the earnings call, as well as future earnings projections.

Since the start of the year, Pulmonx shares have declined approximately 30.8%, compared to a 0.4% drop in the S&P 500 index.

What Lies Ahead for Pulmonx?

Although Pulmonx has lagged behind the broader market this year, investors are now considering the company’s future prospects.

One key factor for investors is the company’s earnings outlook, which includes not only the current consensus for upcoming quarters but also any recent changes in these estimates.

Research indicates a strong link between short-term stock performance and trends in earnings estimate revisions. Investors can monitor these changes themselves or use established rating systems like the Zacks Rank, which has a strong history of leveraging earnings estimate trends.

Prior to this earnings announcement, Pulmonx’s estimate revisions were mixed. The latest results may influence future revisions, but at present, the stock holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the overall market. For a full list of Zacks #1 Rank (Strong Buy) stocks, click here.

It will be important to watch how analyst estimates for the next quarters and the current fiscal year evolve in the coming days. The current consensus projects an EPS of -$0.33 on $22.25 million in revenue for the next quarter, and an EPS of -$1.28 on $93.86 million in revenue for the full year.

Investors should also consider industry trends, as these can significantly affect stock performance. The Medical Info Systems industry currently ranks in the bottom 40% of over 250 Zacks industries. Historically, the top half of Zacks-ranked industries outperforms the bottom half by more than two to one.

Industry Update: TruBridge Yet to Report

Another company in the same sector, TruBridge (TBRG), has not yet released its results for the quarter ending December 2025.

This healthcare IT firm is expected to announce quarterly earnings of $0.41 per share, representing a 720% increase from the prior year. The consensus EPS estimate has remained steady over the past month.

TruBridge’s revenue is forecasted to reach $87.63 million, a slight 0.3% increase from the same quarter last year.

Is Pulmonx Corporation (LUNG) a Good Investment?

Before making an investment decision on Pulmonx Corporation (LUNG), you may want to explore the top stock picks for the next month. Zacks Investment Research offers a complimentary report on the 7 best stocks to buy now.

Since 1978, Zacks Investment Research has provided investors with independent analysis and tools. Over the past 25 years, the Zacks Rank stock-rating system has delivered an average annual return of 24.08%, more than doubling the S&P 500’s performance during the period from January 1, 1988, to May 6, 2024.

Looking for the latest stock recommendations from Zacks? Download the 7 Best Stocks for the Next 30 Days here for free.

• Pulmonx Corporation (LUNG): Free Stock Analysis Report
• TruBridge, Inc. (TBRG): Free Stock Analysis Report